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Abstract
Background: Despite a strong movement towards active patient involvement in healthcare policy decisions,
systematic and explicit consideration of evidence of this research on patient preferences seems limited.
Furthermore, little is known about the opinions of several stakeholders towards consideration of research evidence
on patient preferences in healthcare policy decisions. This paper describes the protocol for an explorative study on
the integration of research on patient preferences in healthcare policy decisions. The study questions: to what
extent research evidence on patient preferences is considered in current procedures for healthcare policy decisions;
opinions of stakeholders regarding the integration of this type of evidence in healthcare policy decisions; and what
could be a decision framework for the integration of such research evidence in healthcare policy decisions.
Methods/design: The study is divided in three sub-studies, predominantly using qualitative methods. The first
sub-study is a scoping review in five European countries to investigate whether and how results of research on patient
preferences are considered in current procedures for coverage decisions and clinical practice guideline development.
The second sub-study is a qualitative study to explore the opinions of stakeholders with regard to the possibilities for
integrating evidence on patient preferences in the process of healthcare decision-making in the Netherlands. The third
sub-study is the development of a decision framework for research on patient preferences. The framework will consist
of: a process description regarding the place of evidence on patient preferences in the decision-making process; and a
taxonomy describing different terminologies and conceptualisations of ‘preferences’ and an overview of existing
methodologies for investigating preferences. The concept framework will be presented to and discussed with experts.
Discussion: This study will create awareness regarding the existence and potential value of research evidence on patient
preferences for healthcare policy decision-making and provides insight in the methods for investigating patient preferences
and the barriers and facilitators for integration of such research in healthcare policy decisions. Results of the study will be
useful for researchers, clinical practice guideline developers, healthcare policy makers, and patient representatives.
Keywords: Patient preference, Coverage decisions, Clinical practice guidelines, Decision framework, Taxonomy
Background
Patient preferences are increasingly considered important
in healthcare policy decision-making, with many stake-
holders explicitly supporting and appreciating patient in-
volvement and consideration of patient preferences [1,2].
It is generally acknowledged that clinicians’ adherence to
guidelines and the uptake of health technologies is deter-
mined by many factors, such as the clinicians’ personal
beliefs and routines. Increasingly, patient-related factors
such as patients’ adherence to treatment, patients’ satisfac-
tion with treatment, and experienced (health) outcomes,
all determined by patient preferences, are seen as import-
ant determinants for clinicians’ adherence to and uptake
of healthcare interventions [3]. Acknowledging the
importance of the patient’s perspective, a large body of
research evidence on patient preferences has become
available [4], and new studies on patient preferences are
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increasingly being funded and embedded in empirical
studies, e.g., randomized clinical trials.
Integrating research evidence on patient preferences in
healthcare policy decisions is relevant for several reasons.
First, most of the outcome measures used in healthcare
(economic) evaluations do not consider patients’ valua-
tions of those outcomes. Consideration of patient prefer-
ences in healthcare policy decisions may therefore
improve the uptake and real-world efficiency of healthcare
technologies in its broadest sense. Second, it may serve as
an important and evidence-based source of information
(e.g., for patient representatives in healthcare decision
making), therefore enhancing consumer empowerment.
Third, providing doctors with results of research on col-
lective patients’ preferences may inform individual patient
preferences in the context of medical decision-making.
Fourth, in general, consideration of patient views is con-
sidered as ethically the right thing to do.
Although currently there is a strong movement to-
wards patient involvement in healthcare policy-making,
systematic and explicit consideration of research evi-
dence on patient preferences in healthcare policy deci-
sions seems limited. Furthermore, little is known about
the opinions of stakeholders towards the consideration
of research evidence on patient preferences in healthcare
policy decisions. Whereas some make a strong plea, or
at least see possibilities, for considering research evi-
dence on patient preferences in either coverage decisions
or clinical practice guideline (CPG) development (e.g.,
[3,5-13]) the literature on this topic also suggests that
there are barriers for the use of scientific data on patient
preferences in healthcare policy decisions. These barriers
stem from normative, psychological, methodological and
practical considerations. For instance, the use of public -
instead of patient - preferences for calculation of Quality
Adjusted Life Years (QALY) in economic evaluations has
a strong normative base [14,15]. Furthermore, the focus in
health economic evaluations is on maximizing health out-
comes, whereas people may attach value to aspects
broader than health (e.g., [16]). Also, there seems to be a
lack of understanding or agreement on the conceptua-
lization and measurement of patient preferences [17].
Others doubt the quality of such research [18], doubt
whether patients are capable of stating their preferences,
or question the relevance of research evidence on patient
preferences (e.g., [19]). Finally, it may be unclear how re-
sults of studies on patient preferences should be weighted
against other arguments in established decision-making
processes (e.g., [3,13]).
The aim of this paper is to describe the study protocol
for an explorative study on the integration of research evi-
dence on patient preferences in healthcare policy decisions
in the Netherlands: the Patient-VIP Study (Patient Values
In Policy-making Study). Results obtained in the
Netherlands will function as a case study that can be used
as a reference for other countries. Two types of policy
decision-making will be addressed: coverage decisions (i.e.,
uptake or removal of a health technology in the benefit
package) and recommendations for decision-making in
CPG development. Regarding coverage decisions, the
study will focus on pharmaceuticals, as in the Netherlands
the decision-making process is most established for this
type of healthcare technology.
For this study, the following research questions have
been defined:
1. To what extent is research evidence on patient
preferences considered in current procedures for
coverage decisions and CPG development, and if so,
how is it considered? (Study 1);
2. What are the opinions and ideas of several
stakeholders with regard to development of a
taxonomy for research on patient preferences, as well
as the possibilities for integrating evidence on patient
preferences in healthcare decision-making regarding
pharmaceuticals and clinical practice guideline
development in the Netherlands? (Study 2);
3. What could be the content of a decision framework
for the integration of evidence on patient
preferences in healthcare decision-making in the
Netherlands (Study 3).
Such a framework may consist of two parts: a process
description regarding the status and position of evidence
on patient preferences in the decision-making processes,
and an onset for a taxonomy describing the different ter-
minologies and conceptualizations of ‘preferences,’ includ-
ing an overview of existing quantitative, qualitative and
mixed methods methodologies for investigating prefer-
ences. Regarding the first part of the decision framework,
existing Dutch decision frameworks for coverage decisions
regarding pharmaceuticals and for CPG development will
be used as the starting point, with the aim to integrate the
use of existing, published data on patient preferences in
these existing frameworks.
The study will be predominantly based on the views,
knowledge and experience of different stakeholders.
Definitions of ‘preference
A dictionary definition of preference is: liking something
better than another; tendency to choose [20]. The term
‘preference’ generally refers to the (relative) ‘desirability’
of something or someone, but is conceptualized and
measured differently across disciplines. In economics,
for example, the desirability of a good or service can be
understood in terms of the concept of utility, referring
to a measure of satisfaction gained from the consump-
tion of a good or service, such as healthcare [14]. Utility
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is related to choices between goods and services, and
this includes the notion of the sacrifice of one option in
order to receive another. Gold and colleagues [15], p. 83
refer to preferences as numerical judgements of the de-
sirability of a set of outcomes, and the term ‘preference’
is used interchangeably with the terms ‘utility’ or ‘value.’
In psychology, desirability is more often represented by
the concept of attitude, defined as a disposition to re-
spond favorably or unfavorably to an object, person,
institution or event [21,22]. Alternatively, the term ‘pref-
erence’ may refer to an evaluative judgement in the
sense of liking or disliking an object (e.g., [23]). In medi-
cine, the term ‘preference’ has been defined as the desir-
ability of a health-related outcome, process, or treatment
choice [11]. As a result of different conceptualizations,
varying terminology and methodology (e.g., [24]) is used
in preference research.
In this study, the term ‘patient preference’ is broadly de-
fined as ‘the value attached by patients to (aspects of)
health and healthcare.’ With this work definition, we are
not a priori excluding specific conceptualizations and/or
measurement techniques, and not a priori confining the
evaluative space to health-related outcomes only, but ex-
tend it with outcomes beyond health and process features.
Current decision frameworks in the Netherlands
Coverage decisions
In healthcare systems, the aim is to make healthcare finan-
cially accessible. The challenge is to ensure that only those
technologies that are safe, efficacious and effective are re-
imbursed [25,26]. Reimbursement decisions are made so
as to ensure the greatest good for a group of patients or
individuals, among others. To achieve this, the use of rele-
vant information and knowledge is essential in the
decision-making process. Informed decision-making can
be enhanced by the preparation of evaluations of health
interventions or health technology assessments (HTAs),
which encompass aspects such as safety, efficacy, effective-
ness, medical necessity, economic efficiency, social impact,
and equity, as well as the quality of the evaluation itself
[27]. Many countries, including the Netherlands, rely on
HTA for crucial technical information. There is increasing
interest in how governments actually make coverage deci-
sions, and their outcomes (e.g., [28,29]).
In the Netherlands, coverage decisions are advised
upon by the Dutch Health Care Insurance Board (CVZ).
(In 2013, the CVZ and its tasks merged into the newly
established ‘Zorginstituut Nederland.’ The ‘Zorginstituut
Nederland’ has the following tasks: the execution of in-
surances and the health basket, improving the quality of
care, and renewing care professions and education). A
detailed description of the benefits and entitlements in
Dutch healthcare and how these are defined can be
found in ‘The health basket in the Netherlands’ [30].
Regarding pharmaceuticals, the decision-making process
is largely structured and involves an assessment phase
and an appraisal phase [31,32]. In the assessment phase,
an analysis is made based on quantifiable criteria to de-
cide whether, in principle, a pharmaceutical should be
funded with collective resources. The assessment phase
is generally guided by four so-called package principles,
being ‘necessity,’ ‘effectiveness,’ ‘cost-effectiveness’ and
‘feasibility.’ The package principle ‘necessity’ refers to
the question of whether a particular disease or
healthcare service justifies a claim on solidarity given the
cultural context, and is addressed through the concept
of disease burden. The ‘effectiveness’ principle refers to
the balance between positive and negative outcomes of
the healthcare service, usually expressed in terms of clin-
ical outcomes, quality of life, and aspects like user
friendliness, and is assessed according to the principles
of Evidence-Based Medicine (EBM) [33]. The ‘cost-ef-
fectiveness’ criterion defines whether the relation be-
tween societal costs and benefits of the healthcare
service is acceptable. In accordance with the Dutch
guideline for pharmaco-economic research [34], cost-
effectiveness should be evaluated in an economic evalu-
ation and expressed using a cost per QALY approach.
The ‘feasibility’ of a healthcare service refers to whether
it is (financially) attainable to include the service in the
benefit package. This is usually addressed by means of
budget impact analysis. Patient preference data could –
according to the principles of EBM – be included in the
effectiveness criterion (it sometimes is through measure-
ment of quality of life in patients or user friendliness).
However, the principles of EBM provide no strict
methodological guidance regarding the use and format
of patient preference information. The appraisal phase
consists of a community review of the outcomes of the
assessment phase, involving the application of non-
quantifiable criteria derived from the principles of
fairness and solidarity, and culminating in a definitive
decision. A patient representative is a member of the
CVZ appraisal committee. An important question in the
context of a decision framework will be whether it is de-
sirable that evidence of patient preferences is integrated
in one of the existing package principles, or whether it
should be issued separately. In the latter case, an import-
ant question is how such evidence should be weighted
against the other criteria in the appraisal phase.
Development of clinical practice guidelines
Clinical practice guidelines are statements that include
recommendations intended to optimize patient care, and
that are informed by a systematic review of available evi-
dence and assessment of the benefits and harms of alter-
native care options [33]. Clinical practice guidelines link
the practice of medicine more closely to the body of
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underlying evidence, shift the burden of evidence review
from the individual practitioner to experts, and aim to
improve the quality of care by synthesizing the available
evidence and expert opinions for relevant clinical prob-
lems. As such, they are an established tool for quality
improvement in clinical practice. Guidelines are sys-
tematically developed in (multidisciplinary) consensus
groups, with grading, interpretation and translation of
evidence into recommendations. The Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) system for rating the quality of evidence and
strength of recommendations is increasingly used [35].
The GRADE system describes four factors that affect the
strength of a recommendation: the quality of evidence
(e.g., homogeneous meta-analysis versus case studies);
uncertainty about the balance between positive and
negative effects (e.g., low versus high levels of toxicity,
costs); uncertainty or variability in values and prefer-
ences (e.g., young patients versus old patients); uncer-
tainty about whether the intervention represents a wise
use of resources (e.g., low versus high costs, favorable
versus unfavorable budget impact analysis). A strong
recommendation means that most informed patients
would choose the recommended management, and that
clinicians can structure their interactions with patients
accordingly. A weak or so-called conditional recommen-
dation means that patients’ choices will vary according
to their values and preferences, and clinicians must
ensure that patients’ care is in line with their values
and preferences.
In the Netherlands, the Dutch Council for Quality of
Health Care had the task of coordinating the deve-
lopment of CPGs. (In January 2013, the Regieraad
was merged into the newly established ‘Zorginstituut
Nederland’ as the ‘Quality Institute’). CPGs are devel-
oped by different guideline developers, such as the
Dutch Institute for Healthcare Improvement (CBO),
professional societies, the Dutch Association of Medical
Specialists, the oncology collaborative groups, and
Trimbos Institute for Research on Mental Health. The
process of CPG development follows the principles of
EBM and the criteria of the Appraisal of Guidelines for
Research and Evaluation (AGREE) Instrument [36] as
guidance. An evidence-based guideline is developed
according to an established process and based on three
sources of knowledge: best available knowledge and
evidence; expertise, experiences and preferences of
healthcare practitioners; and experiential knowledge,
experiences and preferences of patients. The AGREE
instrument makes an explicit reference to research evi-
dence on patient experiences as a potential source of in-
formation. However, as noted, the principles of EBM
provide no strict methodological guidance regarding the
use and format of patient preference information.
Methods
Study design
This study consists of three sub-studies.
Study 1: scoping review
The aim of the scoping review is to investigate whether
and how results of research on patient preferences are
considered in current procedures for coverage decisions
and CPG development. We will search several biblio-
graphic databases and websites for relevant (gray) litera-
ture, as well as reports and documents for the
Netherlands, Germany, England and Wales, Scotland
and France with the aim to get insight in current proce-
dures for coverage decisions and guideline development,
as well as their reference to research on patients’ prefer-
ences. These countries are selected because of relevant
similarities and differences regarding the financing and
regulation of their healthcare system. Furthermore, we
will study the contents of selected coverage decisions
and CPG regarding some major clinical topics on their
reference to research on patient preferences. The scop-
ing review will reveal whether the integration of evi-
dence on patient preferences in healthcare policy
decisions differs between countries. Furthermore, if such
evidence is considered in either one of the countries, it
may inform the development of a decision framework
the Netherlands.
Study 2: qualitative study
The aim of the qualitative study is to explore opinions
and ideas of stakeholders with regard to the term ‘pref-
erence,’ as well as the relevance of research evidence on
patient preferences for healthcare policy decisions. Po-
tential strategies to resolve the barriers and enhance fa-
cilitators for the integration of patient preference data in
healthcare policy decisions will also be issued during the
interviews. First, in-depth semi-structured interviews
will be held with key-informants from several Dutch
stakeholders such as researchers, patient representatives,
guideline developers, and healthcare policymakers. We
aim for a heterogeneous sample of participants with
different perspectives and ideas on how to incorporate
evidence on patient preferences in healthcare decision-
making regarding pharmaceuticals. Although we aim for
interviews with stakeholders that can reflect on both
coverage decision making and guideline development,
we will also turn to specialists on one of these two fields.
The face-to-face or phone interviews will be open and
will be characterized by a personal approach, meaning
that the interviewer has some knowledge of the back-
ground and work of the person to be interviewed, en-
sures that the objective and procedure of the study are
clear, and stimulates the participant to express his or her
opinion by explaining that there are no good or wrong
Dirksen et al. Implementation Science 2013, 8:64 Page 4 of 7
http://www.implementationscience.com/content/8/1/64
answers and that each opinion or idea will be included
in the analysis. After the introduction, the interviewers
will follow the interview scheme, based on a list of
themes and examples to ensure that all relevant items
are brought up during the discussion. Interviews will be
audio-recorded and transcribed verbatim. An independ-
ent senior researcher will carry out the interviews (CU).
Member-checking will be done by sending interview
participants a summary of the main findings, extracted
from their single interviews.
The interviews will be analyzed by directive content ana-
lysis [37]. The data will be divided into simpler text units
for coding that will be entered into a database (Nvivo).
Units of text referring to similar codes will be grouped
and categorized systematically by one central coder, who
is coding all the interviews (CU). For the most informative
interview - in the opinion of the interviewer - of each sub-
set of interviews, a full open coding of the transcript will
be independently executed by the central coder (i.e., inter-
viewer) and three members of the project group (CD, MJ,
TvdW). Differences in coding will be resolved by consen-
sus discussion, face-to-face or by phone. The central coder
will then analyze the other interviews.
Study 3: development of a draft decision framework
In the third study, we will develop a draft framework for
decision-making, based on sub-studies 1 and 2. The frame-
work will consist of a process description regarding the
place of evidence on patient preferences in the decision-
making process, and a taxonomy describing different
terminologies and conceptualizations of ‘preferences,’ includ-
ing an overview of existing methodologies for investigating
preferences. As we expect that the qualitative interviews
will not provide detailed input to enable development of a
final taxonomy, we will perform a (non-systematic) review
in which the most prominent, well-known theoretical or
conceptual models for preferences and decision-making
will be included. These will include, among others, utility
theory [38], health behavior models [39], the behavioral
economic model for decision-making [40], and satisfaction
models [41,42]. Based on this review, a systematic
categorization of related terminologies, conceptualizations
and definitions will be given. Furthermore, we will build on
an existing review [24] to provide an overview of method-
ologies for measurement of preferences. With the draft
taxonomy, we aim to connect the different terminologies
and conceptualizations of preferences to existing measure-
ment techniques. Furthermore, based on sub-studies 1 and
2, we will develop the process description part of the deci-
sion framework, listing recommendations regarding con-
sideration of results of research on patient preferences,
either in coverage decisions or CPG development.
The concept decision framework will be sent to ex-
perts. We will sample well-known Dutch opinion leaders
and experts again from different stakeholders groups. At
least one expert meeting (about 10 participants), which
may take the form of an invitational conference, will be
organized to present the draft decision framework, to
discuss the framework, to identify the most critical parts
and issues, and to define necessary steps towards further
development, validation and implementation of the
framework.
Study status
The study protocol was presented to the medical ethics
committee of the Maastricht University Medical Centre.
The committee concluded that formal approval was not
required for the three sub-studies.
The first two sub-studies of the study are in progress.
The scoping review is in its final stage. The last inter-
views are currently being performed.
Discussion
We presented the research protocol of a project with
three sub-studies focussing on the integration of results
of research on patient preferences in consensus and
decision-making processes of coverage decisions and
clinical practice guideline development. This study will
create awareness regarding the existence and potential
value of research evidence on patient preferences for
healthcare policy decision-making, and provides insight
into the methods for investigating patient preferences
and the barriers and facilitators for integration of such
research evidence in healthcare policy decisions. An im-
portant prerequisite for this integration of research evi-
dence on patient preferences in healthcare policy
decisions is an overview (a taxonomy) of what may con-
stitute evidence in this context. Ultimately, our aim is to
develop a framework that will assist decision-makers in
considering this type of information in coverage deci-
sions and GPG development. We feel that this is the
right time to take up the challenge and to see how
established decision-making processes regarding cover-
age decisions and guideline development can be adapted
in such a way that research on patient preferences gets a
fair weight in policy decisions. In the end, systematic
and explicit use of results of research evidence on pa-
tients’ preferences is the ultimate and only justification
for investing in such research either by governments
through allocation of research budgets or by patients
through their time and effort.
The strength of this study is that we will first describe
a status quo measurement that will be the starting point
for the qualitative interviews and development of the de-
cision framework. Furthermore, this study focuses both
on coverage decisions and on CPG development; in-
creasingly, it is recognized that both ‘worlds’ are to be
connected and that decision-making on these topics
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should be based on the same arguments. This view is,
for example, reflected by the opinion that cost-
effectiveness arguments should systematically be con-
sidered in CPG development [43]. Therefore, several
experts within the fields of health technology assess-
ment/health economics, healthcare policy-making,
evidence-based medicine, and guideline development
will be consulted. A limitation is that this study, except
for the scoping review, is performed within the Dutch
context and results may therefore not directly be trans-
ferable to other countries.
Results of this study will be useful for healthcare pol-
icy decision makers (e.g., members of assessment and
appraisal committees of coverage decision-making, or
advising organizations, ministries of health, guideline
developers, and patient platforms). The target popula-
tion also consists of researchers. First, the study may
stimulate collection of data on patient preferences in
routine healthcare (economic) evaluations when rele-
vant. Second, the decision framework may put specific
demands on future research on patient preferences.
Patient organizations are a specific target group. The
decision framework may also stimulate the professional
staff of a patient organization to collect or retrieve the
evidence on patient preferences in line with the tax-
onomy, so they are always well-prepared for the task of
representing their patient group. During the project,
stakeholders are actively involved through the use of
semi-structured interviews and expert meetings, the lat-
ter to reach consensus on the contents of the decision
framework.
This study is not about active participation of patients in
the process of coverage decisions and CPG development,
but on reaching consensus and improving these decision
processes by systematically and explicitly considering
existing research evidence on patient preferences. Cur-
rently, much attention is devoted to innovative methods
to engage patient and public representatives in healthcare
decisions, which is seen as important by many stakeholder
groups [1,2]. However, patient participation in coverage
decisions or CPG development is not a substitute for sys-
tematically considering research evidence on patient pref-
erences in healthcare decisions (or vice versa). On the
contrary, providing patient representatives (and other
decision-makers) with evidence on patient preferences is
expected to result in better decisions.
Given the complexity of the empirical research on pa-
tient preferences, stemming from various disciplines
using completely different frameworks and methodolo-
gies, it is expected that this study will result in a first
draft and not in a definite, ready to use decision frame-
work. Ultimately, we seek to deliver some bricks with
the aim of building a practical ‘decision framework’ for
the integration of evidence in patient preferences in
healthcare policy decisions. The taxonomy part of the
decision framework will need improvement and valid-
ation in an international context. We also realize that
creating a consistent language for preference-related re-
search and providing a systematic categorization for the
types of preference-related research will not be suffi-
cient. In order to judge research on patient preferences,
we need quality assessment criteria for appraising such
studies and an additional step of evidence synthesis and
grading. Although quality criteria have already been de-
veloped, e.g., for conjoint analysis studies (e.g., [44,45]),
they may be too unspecific with regards to other prefer-
ence elicitation methods. Furthermore, even if we are
able to provide all the necessary ingredients for the deci-
sion framework, it will not provide explicit guidance on
how to weigh evidence on patient preferences against
other arguments in the decision-making process. Despite
these limitations, the first draft of the decision framework
may serve as an important starting point for future inte-
gration of evidence on patient preferences in healthcare
policy decision making.
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